SKYE Key Statistics, Chart & Performance
The current stock price of SKYE is 0.7203 USD. In the past month the price decreased by -23.46%. In the past year, price decreased by -77.21%.
SKYE Technical Analysis
SKYE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SKYE. The financial health of SKYE is average, but there are quite some concerns on its profitability.
SKYE Financial Highlights
Over the last trailing twelve months SKYE reported a non-GAAP Earnings per Share(EPS) of -3.53. The EPS decreased by -218.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.97% | ||
| ROE | -156.02% | ||
| Debt/Equity | 0 |
SKYE Forecast & Estimates
14 analysts have analysed SKYE and the average price target is 8.89 USD. This implies a price increase of 1134.01% is expected in the next year compared to the current price of 0.7203.
SKYE Ownership
SKYE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.32 | 394.585B | ||
| AMGN | AMGEN INC | 16.18 | 202.372B | ||
| GILD | GILEAD SCIENCES INC | 16.51 | 188.186B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.73 | 119.469B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.25 | 82.007B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.21 | 42.275B | ||
| INSM | INSMED INC | N/A | 31.892B | ||
| NTRA | NATERA INC | N/A | 29.062B | ||
| BIIB | BIOGEN INC | 12.42 | 28.432B | ||
| INCY | INCYTE CORP | 12.5 | 21.405B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SKYE
Company Profile
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. The company is headquartered in San Diego, California. The company went IPO on 2014-02-24. The firm is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The firm is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The firm's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Company Info
SKYE BIOSCIENCE INC
11250 El Camino Real, Suite 100
San Diego CALIFORNIA US
Employees: 11
Phone: 18584100266
SKYE BIOSCIENCE INC / SKYE FAQ
What does SKYE do?
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. The company is headquartered in San Diego, California. The company went IPO on 2014-02-24. The firm is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The firm is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The firm's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Can you provide the latest stock price for SKYE BIOSCIENCE INC?
The current stock price of SKYE is 0.7203 USD. The price decreased by -7.33% in the last trading session.
What is the dividend status of SKYE BIOSCIENCE INC?
SKYE does not pay a dividend.
What is the ChartMill technical and fundamental rating of SKYE stock?
SKYE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of SKYE stock?
SKYE BIOSCIENCE INC (SKYE) has a market capitalization of 23.09M USD. This makes SKYE a Nano Cap stock.